ARKAY Therapeutics Announced as a Finalist in Most Successful Early Phase Research in 2019 Clinical & Research Excellence Awards

BOSTON – February 20, 2019ARKAY Therapeutics has been named a finalist in the Most Successful Early Phase Research (Preclinical and Phase I) category in the CARE Awards, which recognize outstanding work across the global clinical research enterprise.

The 2019 winners will be announced at a ceremony on Thursday, 2 May at the Hyatt Regency Boston, MA, where we gather distinguished leaders in the biopharmaceutical, CRO, and diagnostic industries from all corners of the globe.

ARKAY Therapeutics is a privately-held, clinical stage biopharmaceutical company located in East Windsor, NJ.  ARKAY was recognized for its innovative product concept for developing clinically superior yet affordable products for Type 2 diabetes patients worldwide. Unlike the currently marketed treatment options, which treat primarily the symptoms, ARKAY’s products are custom-designed and formulated for providing sustained glycemic control by treating the underlying pathophysiology of pancreatic beta cell failure and insulin resistance.   

The CARE Awards 2019 features 11 categories, which showcase significant accomplishments and highlight innovation across the industry – from rare disease drug development and patient centricity in trials and research, to product and technological development, clinical results and collaborative efforts between individuals, departments, or companies. Entries are judged independently by a panel of experts from all core sectors of the clinical R&D industry.

“It is truly an honor to be recognized and selected as a finalist for the prestigious CARE award” said Ravi Kumar, Founder and CEO of ARKAY Therapeutics. I attribute ARKAY’s success in reaching several important milestones in the last 2-3 years to all the collaborators and members of ARKAY’s stellar advisory board who have provided guidance and generously shared their time. 

You can view the full list of finalists here:

About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit

Back to news